FindTrial
Sign In

Brepocitinib

DRUG5 trials

Sponsors

Priovant Therapeutics Inc., Priovant Therapeutics, Inc.

Conditions

DermatomyositisDermatomyositis, Adult TypeNon-infectious Intermediate UveitisNon-infectious Pan UveitisNon-infectious Posterior Uveitisactive non-infectious uveitis (intermediate uveitispanuveitis)posterior uveitis

Phase 2

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
CompletedNCT05523765
Priovant Therapeutics, Inc.Non-infectious Intermediate Uveitis, Non-infectious Pan Uveitis, Non-infectious Posterior Uveitis
Start: 2022-11-14End: 2024-07-30Updated: 2025-07-25
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
CompletedNCT06433999
Priovant Therapeutics, Inc.Dermatomyositis, Dermatomyositis, Adult Type
Start: 2024-08-28End: 2025-02-28Updated: 2025-05-20

Phase 3

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Active, not recruitingNCT05437263
Priovant Therapeutics, Inc.Dermatomyositis
Start: 2022-10-31End: 2026-07-31Updated: 2025-09-29
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
RecruitingCTIS2022-500367-12-00
Priovant Therapeutics Inc.Dermatomyositis
Start: 2022-11-30Target: 126Updated: 2025-11-26
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Active, not recruitingCTIS2024-515089-15-00
Priovant Therapeutics Inc.active non-infectious uveitis (intermediate uveitis, panuveitis), posterior uveitis
Start: 2025-02-28Target: 105Updated: 2025-12-18